This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $207.63, moving -0.77% from the previous trading session.
Radius (RDUS) Up On Positive Data From Breast Cancer Study
by Zacks Equity Research
Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $206.78, marking a +1.8% move from the previous day.
Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
by Zacks Equity Research
Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.
Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal
by Zacks Equity Research
Zacks Value Trader Highlights: AT&T, Verizon, Amgen, Poshmark, and The RealReal
How to Find Stocks on Sale in 2021
by Tracey Ryniec
Looking for hidden gems isn't too hard with this simple stock screen.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
AstraZeneca (AZN) COVID-19 Antibody Meets Goal in TACKLE Study
by Zacks Equity Research
AstraZeneca (AZN) posts positive results from the phase III TACKLE study on the AZD7442 combo for treating mild-to-moderate COVID-19 in the outpatient setting. The study has met its primary endpoint.
Amgen (AMGN) Reports New Data From Lumakras Combo Study
by Zacks Equity Research
Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.
Bristol Myers (BMY) UC Candidate Fails in Phase II Study
by Zacks Equity Research
Bristol Myers (BMY) suffers a setback as its phase II study of deucravacitinib for the treatment of moderate to severe ulcerative colitis fails to meet primary and secondary endpoints.
Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.
AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Qulipta (atogepant) for preventive treatment of episodic migraine in adults.
The Zacks Analyst Blog Highlights: Tesla, JPMorgan, Oracle, Amgen and Lam Research
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, JPMorgan, Oracle, Amgen and Lam Research
Top Analyst Reports for Tesla, JPMorgan & Oracle
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), JPMorgan Chase & Co. (JPM), and Oracle Corporation (ORCL).
Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails
by Zacks Equity Research
Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.
Amgen (AMGN) Repatha Gets FDA Nod for Expanded Use in Kids
by Zacks Equity Research
FDA approves Amgen's (AMGN) Repatha for pediatric patients, 10 years of age and older, with familial hypercholesterolemia, both heterozygous and homozygous forms.
Onconova (ONTX) KRAS Inhibitor Shows Activity in Lung Cancer
by Zacks Equity Research
Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control potential.
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
by Zacks Equity Research
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
The Zacks Analyst Blog Highlights: Bank of America, PepsiCo, Wells Fargo, T-Mobile and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, PepsiCo, Wells Fargo, T-Mobile and Amgen